{
  "DOI": "10.1038/s41431-020-0677-x",
  "ISSN": [
    "1018-4813",
    "1476-5438"
  ],
  "URL": "http://dx.doi.org/10.1038/s41431-020-0677-x",
  "abstract": "\u003cjats:title\u003eAbstract\u003c/jats:title\u003e\u003cjats:p\u003eThe treatment options for Fabry disease (FD) are enzyme replacement therapy (ERT) with agalsidase alfa or beta, and the oral pharmacological chaperone migalastat. Since few data are available on the effects of switching from ERT to migalastat, we performed a single-center observational study on seven male Fabry patients (18–66 years) to assess the effects of the switch on renal, cardiac, and neurologic function, health status, pain, lyso-Gb3, α-Gal A activity and adverse effects. Data were retrospectively collected at time of diagnosis of FD (baseline, T0), and after 12 months of ERT (T1), and prospectively after 1 year of therapy with migalastat (T2). No patient died or reported renal, cardiac, or cerebrovascular events during the study period. The predefined measures for cardiac, renal and neurologic function, and FD-related symptoms and questionnaires were stable between baseline and the switch, and remained unchanged with migalastat. However, a significant improvement was observed in left ventricular mass index from baseline to T2 (\u003cjats:italic\u003ep\u003c/jats:italic\u003e = 0.016), with a significative difference between the treatments (\u003cjats:italic\u003ep\u003c/jats:italic\u003e = 0.028), and in median proteinuria from T2 vs T1 (\u003cjats:italic\u003ep\u003c/jats:italic\u003e = 0.048). Moreover, scores of the BPI improved from baseline to T1, and remained stable with migalastat. Plasma lyso-Gb3 levels significantly decreased from baseline to T1 (\u003cjats:italic\u003eP\u003c/jats:italic\u003e = 0.007) and T2 (\u003cjats:italic\u003eP\u003c/jats:italic\u003e = 0.003), while did not significantly differ between the two treatments. α-Gal A activity increased from T0 to T2 (\u003cjats:italic\u003ep\u003c/jats:italic\u003e \u0026lt; 0.0001). The frequency of adverse effects under migalastat and ERT was comparable (28% for both drugs). In conclusion, switching from ERT to migalastat is valid, safe and well tolerated.\u003c/jats:p\u003e",
  "alternative-id": [
    "677"
  ],
  "assertion": [
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "Received",
      "name": "received",
      "order": 1,
      "value": "24 January 2020"
    },
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "Revised",
      "name": "revised",
      "order": 2,
      "value": "1 May 2020"
    },
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "Accepted",
      "name": "accepted",
      "order": 3,
      "value": "12 May 2020"
    },
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "First Online",
      "name": "first_online",
      "order": 4,
      "value": "9 July 2020"
    },
    {
      "group": {
        "label": "Compliance with ethical standards",
        "name": "EthicsHeading"
      },
      "name": "Ethics",
      "order": 1
    },
    {
      "group": {
        "label": "Conflict of interest",
        "name": "EthicsHeading"
      },
      "name": "Ethics",
      "order": 2,
      "value": "The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest."
    }
  ],
  "author": [
    {
      "ORCID": "http://orcid.org/0000-0002-5379-1104",
      "affiliation": [],
      "authenticated-orcid": false,
      "family": "Riccio",
      "given": "Eleonora",
      "sequence": "first"
    },
    {
      "affiliation": [],
      "family": "Zanfardino",
      "given": "Mario",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Ferreri",
      "given": "Lucia",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Santoro",
      "given": "Ciro",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Cocozza",
      "given": "Sirio",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Capuano",
      "given": "Ivana",
      "sequence": "additional"
    },
    {
      "ORCID": "http://orcid.org/0000-0003-4414-8464",
      "affiliation": [],
      "authenticated-orcid": false,
      "family": "Imbriaco",
      "given": "Massimo",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Feriozzi",
      "given": "Sandro",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Pisani",
      "given": "Antonio",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Pisani",
      "given": "Antonio",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Riccio",
      "given": "Eleonora",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Cocozza",
      "given": "Sirio",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Santoro",
      "given": "Ciro",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Esposito",
      "given": "Roberta",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Imbriaco",
      "given": "Massimo",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Russo",
      "given": "Camilla",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Di Risi",
      "given": "Teodolinda",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Chiariotti",
      "given": "Lorenzo",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Spinelli",
      "given": "Letizia",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Pontillo",
      "given": "Andrea",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Cuocolo",
      "given": "Alberto",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Cennamo",
      "given": "Gilda",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Colao",
      "given": "Annamaria",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "name": "AFFIINITY Group",
      "sequence": "additional"
    }
  ],
  "container-title": [
    "European Journal of Human Genetics"
  ],
  "content-domain": {
    "crossmark-restriction": false,
    "domain": [
      "link.springer.com"
    ]
  },
  "created": {
    "date-parts": [
      [
        2020,
        7,
        9
      ]
    ],
    "date-time": "2020-07-09T10:05:38Z",
    "timestamp": 1594289138000
  },
  "deposited": {
    "date-parts": [
      [
        2023,
        5,
        20
      ]
    ],
    "date-time": "2023-05-20T21:02:10Z",
    "timestamp": 1684616530000
  },
  "indexed": {
    "date-parts": [
      [
        2024,
        4,
        24
      ]
    ],
    "date-time": "2024-04-24T11:30:28Z",
    "timestamp": 1713958228707
  },
  "is-referenced-by-count": 36,
  "issn-type": [
    {
      "type": "print",
      "value": "1018-4813"
    },
    {
      "type": "electronic",
      "value": "1476-5438"
    }
  ],
  "issue": "12",
  "issued": {
    "date-parts": [
      [
        2020,
        7,
        9
      ]
    ]
  },
  "journal-issue": {
    "issue": "12",
    "published-print": {
      "date-parts": [
        [
          2020,
          12
        ]
      ]
    }
  },
  "language": "en",
  "license": [
    {
      "URL": "https://creativecommons.org/licenses/by/4.0",
      "content-version": "tdm",
      "delay-in-days": 0,
      "start": {
        "date-parts": [
          [
            2020,
            7,
            9
          ]
        ],
        "date-time": "2020-07-09T00:00:00Z",
        "timestamp": 1594252800000
      }
    },
    {
      "URL": "https://creativecommons.org/licenses/by/4.0",
      "content-version": "vor",
      "delay-in-days": 0,
      "start": {
        "date-parts": [
          [
            2020,
            7,
            9
          ]
        ],
        "date-time": "2020-07-09T00:00:00Z",
        "timestamp": 1594252800000
      }
    }
  ],
  "link": [
    {
      "URL": "http://www.nature.com/articles/s41431-020-0677-x.pdf",
      "content-type": "application/pdf",
      "content-version": "vor",
      "intended-application": "text-mining"
    },
    {
      "URL": "http://www.nature.com/articles/s41431-020-0677-x",
      "content-type": "text/html",
      "content-version": "vor",
      "intended-application": "text-mining"
    },
    {
      "URL": "http://www.nature.com/articles/s41431-020-0677-x.pdf",
      "content-type": "application/pdf",
      "content-version": "vor",
      "intended-application": "similarity-checking"
    }
  ],
  "member": "297",
  "page": "1662-1668",
  "prefix": "10.1038",
  "published": {
    "date-parts": [
      [
        2020,
        7,
        9
      ]
    ]
  },
  "published-online": {
    "date-parts": [
      [
        2020,
        7,
        9
      ]
    ]
  },
  "published-print": {
    "date-parts": [
      [
        2020,
        12
      ]
    ]
  },
  "publisher": "Springer Science and Business Media LLC",
  "reference": [
    {
      "DOI": "10.1016/j.ymgme.2018.02.014",
      "author": "A Ortiz",
      "doi-asserted-by": "publisher",
      "first-page": "416",
      "journal-title": "Mol Genet Metab",
      "key": "677_CR1",
      "unstructured": "Ortiz A, Germain DP, Desnick RJ, Politei J, Mauer M, Burlina A, et al. Fabry disease revisited: management and treatment recommendations for adult patients. Mol Genet Metab. 2018;123:416–27.",
      "volume": "123",
      "year": "2018"
    },
    {
      "DOI": "10.1159/000448968",
      "author": "D Oder",
      "doi-asserted-by": "publisher",
      "first-page": "30",
      "journal-title": "Nephron",
      "key": "677_CR2",
      "unstructured": "Oder D, Nordbeck P, Wanner C. Long term treatment with enzyme replacement therapy in patients with fabry disease. Nephron. 2016;134:30–6.",
      "volume": "134",
      "year": "2016"
    },
    {
      "DOI": "10.1371/journal.pone.0182379",
      "author": "M Arends",
      "doi-asserted-by": "publisher",
      "first-page": "e0182379",
      "journal-title": "PLoS ONE",
      "key": "677_CR3",
      "unstructured": "Arends M, Biegstraaten M, Hughes DA, Mehta A, Elliott PM, Oder D, et al. Retrospective study of long-term outcomes of enzyme replacement therapy in Fabry disease: analysis of prognostic factors. PLoS ONE. 2017;12:e0182379.",
      "volume": "12",
      "year": "2017"
    },
    {
      "DOI": "10.1016/j.ymgme.2012.08.003",
      "author": "A Pisani",
      "doi-asserted-by": "publisher",
      "first-page": "267",
      "journal-title": "Mol Genet Metab",
      "key": "677_CR4",
      "unstructured": "Pisani A, Visciano B, Roux GD, Sabbatini M, Porto C, Parenti G, Imbriaco M. Enzyme replacement therapy in patients with Fabry disease: state of the art and review of the literature. Mol Genet Metab. 2012;107:267–75.",
      "volume": "107",
      "year": "2012"
    },
    {
      "DOI": "10.1186/1750-1172-5-30",
      "author": "DP Germain",
      "doi-asserted-by": "publisher",
      "journal-title": "Orphanet J Rare Dis",
      "key": "677_CR5",
      "unstructured": "Germain DP. Fabry disease. Orphanet J Rare Dis. 2010;5:30.",
      "volume": "5",
      "year": "2010"
    },
    {
      "DOI": "10.1097/GIM.0b013e3181f13b75",
      "author": "O Lidove",
      "doi-asserted-by": "publisher",
      "first-page": "668",
      "journal-title": "Genet Med",
      "key": "677_CR6",
      "unstructured": "Lidove O, West ML, Pintos-Morell G, Reisin R, Nicholls K, Figuera LE, et al. Effects of enzyme replacement therapy in Fabry disease - a comprehensive review of the medical literature. Genet Med. 2010;12:668–79.",
      "volume": "12",
      "year": "2010"
    },
    {
      "DOI": "10.1016/j.kint.2016.10.004",
      "author": "R Schifmann",
      "doi-asserted-by": "publisher",
      "first-page": "284",
      "journal-title": "Kidney Int",
      "key": "677_CR7",
      "unstructured": "Schifmann R, Hughes DA, Linthorst GE, Ortiz A, Svarstad E, Warnock DG, et al. Screening, diagnosis, and management of patients with Fabry disease: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) controversies conference. Kidney Int. 2017;91:284–93.",
      "volume": "91",
      "year": "2017"
    },
    {
      "DOI": "10.1038/4801",
      "author": "JQ Fan",
      "doi-asserted-by": "publisher",
      "first-page": "112",
      "journal-title": "Nat Med",
      "key": "677_CR8",
      "unstructured": "Fan JQ, Ishii S, Asano N, Suzuki Y. Accelerated transport and maturation of lysosomal α-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor. Nat Med. 1999;5:112–5.",
      "volume": "5",
      "year": "1999"
    },
    {
      "DOI": "10.1007/s10545-009-1077-0",
      "author": "ER Benjamin",
      "doi-asserted-by": "publisher",
      "first-page": "424",
      "journal-title": "J Inherit Metab Dis",
      "key": "677_CR9",
      "unstructured": "Benjamin ER, Flanagan JJ, Schilling A, Chang HH, Agarwal L, Katz E, et al. The pharmacological chaperone 1- deoxygalactonojirimycin increases α-galactosidase A levels in Fabry patient cell lines. J Inherit Metab Dis. 2009;32:424–40.",
      "volume": "32",
      "year": "2009"
    },
    {
      "DOI": "10.5414/CPP47111",
      "author": "D Germain",
      "doi-asserted-by": "publisher",
      "first-page": "S111",
      "journal-title": "Int J Clin Pharm Ther",
      "key": "677_CR10",
      "unstructured": "Germain D, Fan JQ. Pharmacological chaperone therapy by active- site- specific chaperones in Fabry disease: in vitro and preclinical studies. Int J Clin Pharm Ther. 2009;47:S111–7.",
      "volume": "47",
      "year": "2009"
    },
    {
      "DOI": "10.1056/NEJMoa1510198",
      "author": "DP Germain",
      "doi-asserted-by": "publisher",
      "first-page": "545",
      "journal-title": "N. Engl J Med",
      "key": "677_CR11",
      "unstructured": "Germain DP, Hughes DA, Nicholls K, Bichet DG, Giugliani R, Wilcox WR, et al. Treatment of Fabry’s disease with the pharmacologic chaperone migalastat. N. Engl J Med. 2016;375:545–55.",
      "volume": "375",
      "year": "2016"
    },
    {
      "DOI": "10.1136/jmedgenet-2016-104178",
      "author": "DA Hughes",
      "doi-asserted-by": "publisher",
      "first-page": "288",
      "journal-title": "J Med Genet",
      "key": "677_CR12",
      "unstructured": "Hughes DA, Nicholls K, Shankar SP, Sunder-Plassmann G, Koeller D, Nedd K, et al. Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study. J Med Genet. 2017;54:288–96.",
      "volume": "54",
      "year": "2017"
    },
    {
      "DOI": "10.1002/ajmg.a.61105",
      "author": "DA Hughes",
      "doi-asserted-by": "publisher",
      "first-page": "1069",
      "journal-title": "Am J Med Genet",
      "key": "677_CR13",
      "unstructured": "Hughes DA, Nicholls K, Sunder-Plassmann G, Jovanovic A, Feldt-Rasmussen U, Schiffmann R, et al. Safety of switching to Migalastat from enzyme replacement therapy in Fabry disease: experience from the Phase 3 ATTRACT study. Am J Med Genet. 2019;179:1069–73.",
      "volume": "179",
      "year": "2019"
    },
    {
      "key": "677_CR14",
      "unstructured": "European Medicines Agency. Migalastat (Galafold): EU summary of product characteristics. 2018. https://www.ema.europa.eu/. Accessed 16 Jul 2019."
    },
    {
      "DOI": "10.1002/cpt.1321",
      "author": "J Müntze",
      "doi-asserted-by": "publisher",
      "first-page": "1224",
      "journal-title": "Clin Pharm Ther",
      "key": "677_CR15",
      "unstructured": "Müntze J, Gensler D, Maniuc O, Liu D, Cairns T, Oder D, et al. Oral chaperone therapy Migalastat for treating Fabry disease: enzymatic response and serum biomarker changes after 1 year. Clin Pharm Ther. 2019;105:1224–33.",
      "volume": "105",
      "year": "2019"
    },
    {
      "DOI": "10.1038/gim.2016.122",
      "author": "ER Benjamin",
      "doi-asserted-by": "publisher",
      "first-page": "430",
      "journal-title": "Genet Med",
      "key": "677_CR16",
      "unstructured": "Benjamin ER, Della Valle MC, Wu X, Katz E, Pruthi F, Bond S, et al. The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat. Genet Med. 2017;19:430–8.",
      "volume": "19",
      "year": "2017"
    },
    {
      "key": "677_CR17",
      "unstructured": "Amicus Therapeutics Inc, 2018 FDA approves Galafold TM (migalastat) for the treatment of certain adult patients with Fabry disease [news release]. Cranbury, NJ: Amicus Therapeutics, Inc. Retrieved from http://ir.amicusrx.com/news-releases/news-release-details/fda-approves-galfoldtm-migalastat-treatemnt-cretain-adult. Accessed 19 Mar 2019."
    },
    {
      "DOI": "10.7326/0003-4819-150-9-200905050-00006",
      "author": "AS Levey",
      "doi-asserted-by": "publisher",
      "first-page": "604",
      "journal-title": "Ann Intern Med",
      "key": "677_CR18",
      "unstructured": "Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration): A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–12.",
      "volume": "150",
      "year": "2009"
    },
    {
      "DOI": "10.1016/j.jpain.2003.12.005",
      "author": "G Tan",
      "doi-asserted-by": "publisher",
      "first-page": "133",
      "journal-title": "J Pain",
      "key": "677_CR19",
      "unstructured": "Tan G, Jensen MP, Thornby JI, Shanti BF. Validation of the brief pain inventory for chronic non malignant pain. J Pain. 2004;5:133–7.",
      "volume": "5",
      "year": "2004"
    },
    {
      "DOI": "10.1111/j.1399-0004.2004.00219.x",
      "author": "C Whybra",
      "doi-asserted-by": "publisher",
      "first-page": "299",
      "journal-title": "Clin Genet",
      "key": "677_CR20",
      "unstructured": "Whybra C, Kampmann C, Krummenauer F, Ries M, Mengel E, Miebach E, et al. The Mainz Severity Score Index: a new instrument for quantifying the Anderson–Fabry disease phenotype, and the response of patients to enzyme replacement therapy. Clin Genet. 2004;65:299–307.",
      "volume": "65",
      "year": "2004"
    },
    {
      "key": "677_CR21",
      "unstructured": "Ware JE. SF-36 Health Survey: Manual and Interpretation Guide (The Health Institute, New England Medical Centre, Boston, MA, 1997)."
    },
    {
      "DOI": "10.1016/0168-8510(90)90421-9",
      "author": "The EuroQoL Group.",
      "doi-asserted-by": "publisher",
      "first-page": "199",
      "journal-title": "Health Policy",
      "key": "677_CR22",
      "unstructured": "The EuroQoL Group. EuroQoL-a new facility for the measurement of health related quality of life. Health Policy. 1990;16:199–208.",
      "volume": "16",
      "year": "1990"
    },
    {
      "DOI": "10.1089/adt.2011.0370",
      "author": "KJ Valenzano",
      "doi-asserted-by": "publisher",
      "first-page": "213",
      "journal-title": "Assay Drug Dev Technol",
      "key": "677_CR23",
      "unstructured": "Valenzano KJ, Khanna R, Powe AC, Boyd R, Lee G, Flanagan JJ, Benjamin ER. Identification and characterization of pharmacological chaperones to correct enzyme deficiencies in lysosomal storage disorders. Assay Drug Dev Technol. 2011;9:213–35.",
      "volume": "9",
      "year": "2011"
    },
    {
      "DOI": "10.1681/ASN.2014121226",
      "author": "M Lenders",
      "doi-asserted-by": "publisher",
      "first-page": "256",
      "journal-title": "J Am Soc Nephrol",
      "key": "677_CR24",
      "unstructured": "Lenders M, Stypmann J, Duning T, Schmitz B, Brand SM, Brand E. Serum-mediated inhibition of enzyme replacement therapy in Fabry disease. J Am Soc Nephrol. 2016;27:256–64.",
      "volume": "27",
      "year": "2016"
    },
    {
      "DOI": "10.1002/cpdd.1",
      "author": "FK Johnson",
      "doi-asserted-by": "publisher",
      "first-page": "120",
      "journal-title": "Clin Pharm Drug Dev",
      "key": "677_CR25",
      "unstructured": "Johnson FK, Mudd PN, Bragat A, Adera M, Boudes P. Pharmacokinetics and safety of migalastat HCl and effects on agalsidase activity in healthy volunteers. Clin Pharm Drug Dev. 2013;2:120–32.",
      "volume": "2",
      "year": "2013"
    },
    {
      "DOI": "10.1038/mt.2009.220",
      "author": "R Khanna",
      "doi-asserted-by": "publisher",
      "first-page": "23",
      "journal-title": "Mol Ther",
      "key": "677_CR26",
      "unstructured": "Khanna R, Soska R, Lun Y, Feng J, Frascella M, Young B, et al. The pharmacological chaperone 1-deoxygalactonojirimycin reduces tissue globotriaosylceramide levels in a mouse model of Fabry disease. Mol Ther. 2010;18:23–33.",
      "volume": "18",
      "year": "2010"
    },
    {
      "author": "R Schiffmann",
      "first-page": "i346",
      "issue": "Suppl. 1",
      "journal-title": "Nephrol Dial Transpl",
      "key": "677_CR27",
      "unstructured": "Schiffmann R, Bichet D, Germain D, Giugliani R, Hughes DA, Nicholls K, et al. Effects of long-term migalastat treatment on renal function by baseline proteinuria in patients (PTS) with Fabry disease [abstract no. SP004 and poster]. Nephrol Dial Transpl. 2018;33(Suppl. 1):i346–7.",
      "volume": "33",
      "year": "2018"
    },
    {
      "author": "A Jovanovic",
      "first-page": "1",
      "journal-title": "J Inborn Errors Metab Screen",
      "key": "677_CR28",
      "unstructured": "Jovanovic A, Schiffmann R, Nicholls K. Improvements in cardiac mass with long-term migalastat treatment in patients with Fabry disease: results from phase 3 trials [abstract no. LBN 02]. J Inborn Errors Metab Screen. 2017;5:1–2.",
      "volume": "5",
      "year": "2017"
    },
    {
      "DOI": "10.1038/s41436-019-0451-z",
      "author": "DP Germain",
      "doi-asserted-by": "publisher",
      "first-page": "1987",
      "journal-title": "Genet Med",
      "key": "677_CR29",
      "unstructured": "Germain DP, Nicholls K, Giugliani R, Bichet DG, Hughes DA, Barisoni LM, et al. Efficacy of the pharmacologic chaperone migalastat in a subset of male patients with the classic phenotype of Fabry disease and migalastat-amenable variants: data from the phase 3 randomized, multicenter, double-blind clinical trial and extension study. Genet Med. 2019;21:1987–97.",
      "volume": "21",
      "year": "2019"
    }
  ],
  "reference-count": 29,
  "references-count": 29,
  "resource": {
    "primary": {
      "URL": "https://www.nature.com/articles/s41431-020-0677-x"
    }
  },
  "score": 0,
  "short-container-title": [
    "Eur J Hum Genet"
  ],
  "source": "Crossref",
  "title": [
    "Switch from enzyme replacement therapy to oral chaperone migalastat for treating fabry disease: real-life data"
  ],
  "type": "journal-article",
  "update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy",
  "volume": "28"
}